Not Signed In - Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly Prolongs Time To Progression In Previously Treated Multiple Myeloma Patients
Tue, 12 Dec 2006 08:00 AM EST
... Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and VELCADE(R) (bortezomib), the market leader in relapsed or refractory multiple myeloma (MM), report that the combination of medications provides a nearly three-month improvement in time to disease [click link for full article] ...
Related Topics
- Myeloma, Multiple
- Multiple Myeloma
- Myeloma
- Doxorubicin Liposomal Injection
- Data Analysis
- Thalidomide
- Multiple myeloma cancer
- Plasma Cell Neoplasm/Multiple Myeloma
- Multiple Myeloma/Other Plasma Cell Neoplasms
- Multiple Myeloma/Plasma Cell Neoplasm
- Bortezomib
- Multiple Chemical Sensitivity
- Progression to stupor or coma
- Combination Vaccines
- Confusion and changes in mental status may develop if the condition is not treated.
- Fatigue and shortness of breath (if poor heart function isn't treated)
- Twins, Triplets, Multiple Births
- more...
- Multiple System Atrophy
- Combination Diet
email this page
print this page
bookmark this page
feedback on this page
